Therapy Areas: Respiratory
CorestemChemon presents Neuronata-R Phase 3 results at PACTALS 2025
18 September 2025 - CorestemChemon Inc (KOSDAQ:166480), a South Korea-based biotech company, announced on Wednesday that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R (l...
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
17 September 2025 - Biopharmaceutical company AstraZeneca plc (LSE: AZN) (STO: AZN) (Nasdaq: AZN) reported on Wednesday that its Phase III RESOLUTE trial of Fasenra (benralizumab) in chronic obstructi...
GSK commits USD30bn to US R&D and manufacturing expansion
17 September 2025 - Biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) announced on Wednesday that it will invest USD30bn in research, development, and manufacturing infrastructure across the Unit...
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
10 September 2025 - Hydrosome Labs, a US biotechnology company focused on ultrafine bubble (UFB) technology, on Tuesday reported new findings from a study with Biocell Energetics, a venture from the U...
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
9 September 2025 - US pharmaceutical company Amgen (NASDAQ:AMGN) and Japan-based Kyowa Kirin Co Ltd (TSE:4151) announced on Monday preliminary top-line results from the ASCEND study evaluating rocatin...
Johnson & Johnson's Phase 3 MARIPOSA study shows RYBREVANT and LAZCLUZE prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer
8 September 2025 - Johnson & Johnson (NYSE:JNJ), a US-based pharmaceutical and biotechnology company, reported on Saturday that new analyses from the Phase 3 MARIPOSA study shows that first-line t...